DeepMind’s AlphaFold-3 was released in 2025, capable of predicting protein-ligand interactions with near-perfect accuracy. This version expanded on its predecessor by modeling complex protein interactions, vital for drug discovery and biotechnology. Scientists used AlphaFold-3 to rapidly simulate thousands of proteins involved in neurodegenerative diseases. This accelerated the path toward new treatments for conditions like Alzheimer’s and Parkinson’s.

The AI’s open-access model allowed global collaboration. It demonstrated how artificial intelligence could revolutionize life sciences, making drug development faster, cheaper, and more effective. AlphaFold’s success highlights the future of biology and AI synergy.